Optimized ACE2 Decoys Neutralize Antibody-Resistant SARS-CoV-2 Variants through Functional Receptor Mimicry and Treat Infection In Vivo

Scientists compared several enzymatically inactive, Fc effector–silenced ACE2-Fc decoys. Inclusion of the ACE2 collectrin-like domain not only improved affinity for the spike protein, but also unexpectedly extended serum half-life and was necessary to reduce disease severity and viral titer in Syrian hamsters.